CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
about
Antidepressants for smoking cessationNew mechanisms and perspectives in nicotine withdrawalGene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomesAssociation of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokersIdentification and Structural Characterization of Three New Metabolites of Bupropion in HumansPharmacogenetic Optimization of Smoking Cessation Treatment.Organic cation transporter variation and response to smoking cessation therapiesInvolvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapiesBiomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In VivoStereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MSInfluence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial.Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies.Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects.
P2860
Q24201167-7219F56F-FB1E-48E2-950F-7496D0B5CF56Q28111991-7753204F-0BFB-477F-A846-D929D97C5EBDQ28247305-A181C8CB-ED6B-469F-A90C-30BA3C437DF5Q33953232-3EDE2853-D0A6-4333-B32F-19AB40F807C8Q34540994-361E5659-A5E3-4E5F-B85F-E51D08B3DC6CQ34542169-F2049E41-CEE7-4B26-A114-C9288D471C5FQ34974830-B7D2F7A3-2D07-467F-B766-C92C9C765CF0Q35694111-1493F891-7136-4C80-9CF9-5207E39B9692Q35751986-52F2C162-006B-45F6-823D-285B0C3DAF55Q36737009-C0478970-EF61-4711-83D4-98877609752CQ36900154-5163AC7A-A9D0-43B7-8696-5C191DEA5696Q37148882-2169D47F-1263-4461-BC9B-0939E6EE4092Q37273823-2BA69B00-12D0-4203-BB12-72F10DD8DBB8Q37325773-F5F4BFC8-D41D-4AD0-9EBE-06C3C2F4561DQ37596743-1294E1A1-4CD8-49E4-B0E9-C64C28EF225EQ39519725-E83C8289-D9A4-4F0E-B2E0-006C3C833DF5Q42407006-822CEA36-3876-4B26-9197-C01A578AE900Q42713259-AA3BCC19-D99B-43F7-B5FB-F9893640B0E5Q46472801-9CDF3F6C-990B-48CD-838B-12418CCCF7CCQ47267937-931AA486-C0B8-468A-BF18-C000B15E9C2DQ48015634-93D5F8EC-BAA7-4186-9236-9C0DB245F18BQ48285456-9D73E57C-0C5E-4594-922D-3C6E1873D910Q54260617-3B744CC4-637A-46A3-9BFF-BB0DA9A9AFD3Q54412899-4D83353A-F5C7-4090-B636-FC3D3E19C429Q55262171-17C3F385-37F0-4033-B673-26EC77C80AC0
P2860
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@ast
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@en
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@nl
type
label
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@ast
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@en
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@nl
prefLabel
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@ast
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@en
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@nl
P2093
P2860
P356
P1476
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion
@en
P2093
J S Ahluwalia
K S Okuyemi
N L Benowitz
R F Tyndale
P2860
P356
10.1038/CLPT.2012.186
P407
P577
2012-12-01T00:00:00Z